IXICO plc (IXI) Fair Value & Analysis
Healthcare · GB · Market cap 18.9M GBX
Fair value as of: Jun 26, 2026
From 1 valuation models · updated 4 days ago
Fair value updated Jun 26, 2026 — revised from £0.2400 to £0.0300 (−87.5%) since Jun 24, 2026. Share price −4.0% over the past month.
Price vs Fair Value (12 months)
12‑month range £0.0674 – £0.1425 · fair‑value band £0.0215 – £0.0300 · the £0.0845 price screens above the £0.0300 fair value. As of Jun 26, 2026.
✦ Find undervalued quality stocks — 35,000+ analysed Find stocks →Analysis
IXICO plc (IXI) currently trades at £0.0845, while our model-based Fair Value estimate is £0.0300 — implying the stock looks roughly 64.5% overvalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).
Over the trailing twelve months, IXICO plc generated revenue of £7.3M at a net margin of -25.0%. Revenue grew 23.1% year over year. It earns a return on equity of -15.8%. The balance sheet holds a net cash position of £3.4M. Fundamentals as of Jun 26, 2026
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jun 26, 2026. TTM = trailing twelve months.
About the company
IXICO plc provides data analytics services to biopharmaceutical industry in the United States, the United Kingdom, the Netherlands, Denmark, Switzerland, Ireland, Europe, and internationally. The company offers collection, analysis, management, and reporting on gathered clinical study data; neurological diseases data collection and analysis; and sales and marketing services. It also provides imaging contract research organization solutions, including imaging biomarkers, such as radiological reads, volumetric MRI, PET and SPECT, and advanced MRI; trial management; data analytics; post marketing surveillance and clinical diagnostics; and consultancy services. In addition, the company offers IXICO platform, an AI-enabled technology platform for neuroimaging data management and analysis. Its services are used for various therapeutic areas comprising Alzheimer's, Huntington's, Multiple Sclerosis, and Parkinson's diseases, as well as other rare neurological diseases, other Demyelinating d…
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
IXICO plc reported revenue of £6.5M in FY2025 versus £9.2M in FY2021, a compound −8.2%/yr. Reported net income was −£1.7M in FY2025.
Open the full interactive analysis →
Similar stocks
6 more Biotechnology stocks, each showing price versus our Fair Value estimate (as of Jun 26, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Vertex Pharmaceuticals Incorporated VRTX34 | R$574.00 | R$357.63 | -38% |
| Regeneron Pharmaceuticals, Inc REGN | $601.65 | $577.20 | -4% |
| UCB SA UCB | €247.60 | €180.06 | -27% |
| argenx SE ARGNF | $900.00 | $382.64 | -57% |
| Alnylam Pharmaceuticals, Inc ALNY | $303.64 | $110.31 | -64% |
| Samsung Biologics Co 207940 | 1,000,000 KRW | 724,332 KRW | -28% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is IXICO plc (IXI) undervalued?
What is the fair value of IXI?
What is the quality score of IXI?
What is the revenue of IXICO plc (IXI)?
What is the net profit margin of IXI?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.